OTC · Financial Statements
Allergy Therapeutics plc (AGYTF) Financial Statements
$0.15
OTC: AGYTF
Market Cap $756.30M
Overview Financials Dividend
Allergy Therapeutics plc most recently reported annual revenue of $76.0M, a net loss of $55.0M. Revenue declined at an average annual rate of 0.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $84.0M $73.0M $60.0M $55.0M $76.0M Operating Profit $4.0M $-12.0M $-40.0M $-35.0M $-28.0M Net Profit $3.0M $-14.0M $-43.0M $-40.0M $-55.0M EPS $0.00 $-0.01 $-0.04 $-0.01 $-0.01 Op Margin 4.8% -16.8% -66.5% -63.9% -37.3%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $88.0M $74.0M $67.0M $65.0M $68.0M Total Liabilities $40.0M $35.0M $65.0M $61.0M $131.0M Cash $40.0M $21.0M $15.0M $13.0M $18.0M Borrowings $11.0M $11.0M $36.0M $31.0M $60.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $8.0M $-14.0M $-29.0M $-32.0M $-39.0M Investing Cash Flow $-5.0M $-6.0M $-9.0M $-5.0M $-9.0M Financing Cash Flow $-2.0M $-2.0M $-4.0M $-5.0M $9.0M Net Cash Flow $3.0M $-20.0M $-6.0M $-2.0M $1.0M Free Cash Flow $6.0M $-18.0M $-34.0M $-36.0M $-44.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.36 EV / EBITDA -8.21 FCF Yield -14.81% Quick Ratio 0.70 Interest Coverage -4.41 Return 1Y 76.47% Return 3Y -14.29% Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .